Manufacturing

FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.

SKAN’s new Cellana isolator is designed for GMP manufacturing of ATMPs.

Fareva plans to use blow-fill-seal equipment and ApiJect’s prefilled injector technology to create fill/finish capacity in France.

New processes, automation, and digitalization were highlighted in 2021.

Guide addresses challenges of applying GMPs to autologous cell therapy manufacturing.

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.

Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

A new Cytiva FlexFactory platform will be installed at Taiyo Pharma Tech’s site in Osaka, Japan.

Fujifilm’s new cell culture media manufacturing facility in the Netherlands has officially opened.

The additions to Crown Bioscience’s UK facility will increase and expand the company’s current in-vivo offering.

Fujifilm’s center adds local support in Suzhou, China for cell culture media optimization.

Moderna’s agreement with the UK government includes 29 million COVID-19 vaccine doses for delivery in 2022 and 31 million doses for delivery in 2023.

High price tags threaten to block patient access to potentially life-saving cures and treatments.

Bio/pharmaceutical manufacturing harnesses the benefits of digital transformation.

Polpharma implemented digital technologies, including a digital twin of operations.

Isolators move into smaller-volume processes, including cell and gene therapy manufacturing.

Simple, inexpensive real-time analytics are urgently needed for high value products.

Particle analysis is a critical component of pharmaceutical development, providing assurances of the quality and performance of the final dosage form.

Lean delivery offers a promising solution to supply and manufacturing bottlenecks by integrating project teams early on and widening the team’s field of view.

Sartorius is investing €100 million (US$113 million) between 2021 and 2025 to expand capacities for production, innovation, and storage at its French facilities in Aubagne, Cergy, and Lourdes.

Sartorius will invest approximately €270 million (US$305 million) to expand its biopharmaceutical manufacturing activities in South Korea’s biopharm hub.

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers that should continue in the future.

The GEA kytero combines the high performance of larger GEA stainless-steel pharmaceutical centrifuges with the benefits offered by disposable components.

Relative to prior models, the Thermo Scientific Orbitrap Exploris MX mass detector provides reduced downtime and maintenance, superior data quality, and seamless method transfers.